HK1083009A1 - Topical drug delivery using phosphatidylcholine - Google Patents

Topical drug delivery using phosphatidylcholine

Info

Publication number
HK1083009A1
HK1083009A1 HK06103057A HK06103057A HK1083009A1 HK 1083009 A1 HK1083009 A1 HK 1083009A1 HK 06103057 A HK06103057 A HK 06103057A HK 06103057 A HK06103057 A HK 06103057A HK 1083009 A1 HK1083009 A1 HK 1083009A1
Authority
HK
Hong Kong
Prior art keywords
phosphatidylcholine
drug delivery
topical drug
drug
composition
Prior art date
Application number
HK06103057A
Other languages
English (en)
Inventor
Nicholas V Perricone
Original Assignee
Transdermal Biotechnology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transdermal Biotechnology Inc filed Critical Transdermal Biotechnology Inc
Publication of HK1083009A1 publication Critical patent/HK1083009A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/07—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of capsules or similar small containers for oral use
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/23—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/56—Protease inhibitors from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1277—Processes for preparing; Proliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Reproductive Health (AREA)
  • Botany (AREA)
  • Inorganic Chemistry (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK06103057A 2002-05-31 2006-03-09 Topical drug delivery using phosphatidylcholine HK1083009A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US38459702P 2002-05-31 2002-05-31
US10/448,632 US20040018237A1 (en) 2002-05-31 2003-05-30 Topical drug delivery using phosphatidylcholine
PCT/US2003/017220 WO2003101480A1 (fr) 2002-05-31 2003-06-02 Administration topique de medicament a l'aide de phosphatidylcholine

Publications (1)

Publication Number Publication Date
HK1083009A1 true HK1083009A1 (en) 2006-06-23

Family

ID=29715338

Family Applications (1)

Application Number Title Priority Date Filing Date
HK06103057A HK1083009A1 (en) 2002-05-31 2006-03-09 Topical drug delivery using phosphatidylcholine

Country Status (10)

Country Link
US (14) US20040018237A1 (fr)
EP (1) EP1509243B1 (fr)
JP (1) JP2005531595A (fr)
CN (1) CN100509054C (fr)
AU (1) AU2003231943B2 (fr)
CA (1) CA2487305A1 (fr)
ES (1) ES2632912T3 (fr)
HK (1) HK1083009A1 (fr)
IL (2) IL165480A0 (fr)
WO (1) WO2003101480A1 (fr)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040018237A1 (en) * 2002-05-31 2004-01-29 Perricone Nicholas V. Topical drug delivery using phosphatidylcholine
AU2002950713A0 (en) 2002-08-09 2002-09-12 Vital Health Sciences Pty Ltd Carrier
MX2007015949A (es) 2005-06-17 2008-03-07 Vital Health Sciences Pty Ltd Un vehiculo que comprende uno o mas derivados de fosfato de di- y/o mono-(agentes de transferencia de electrones) o complejos de los mismos.
US20070148222A1 (en) * 2005-12-28 2007-06-28 Discovery Partners Llc Skin treatment compositions containing copper-pigment complexes
US20070148224A1 (en) * 2005-12-28 2007-06-28 Discovery Partners Llc Skin treatment compositions containing copper-pigment complexes
US9216197B2 (en) * 2006-09-11 2015-12-22 Biomas Ltd. Topical formulations of tellurium-containing compounds
US20080317836A1 (en) * 2007-06-19 2008-12-25 Discovery Partners Llc Topical compositions for anti-aging skin treatment
US20100068235A1 (en) * 2008-09-16 2010-03-18 Searete LLC, a limited liability corporation of Deleware Individualizable dosage form
US20100068254A1 (en) * 2008-09-16 2010-03-18 Mahalaxmi Gita Bangera Modifying a medicament availability state of a final dosage form
US20100068153A1 (en) * 2008-09-16 2010-03-18 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Ex vivo activatable final dosage form
US20100068256A1 (en) * 2008-09-16 2010-03-18 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Ex vivo modifiable medicament release-substance
US20100068275A1 (en) * 2008-09-16 2010-03-18 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Personalizable dosage form
US20100068233A1 (en) * 2008-09-16 2010-03-18 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Modifiable dosage form
US20100069821A1 (en) * 2008-09-16 2010-03-18 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Ex vivo modifiable medicament release-sites final dosage form
US20100068152A1 (en) * 2008-09-16 2010-03-18 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Ex vivo modifiable particle or polymeric based final dosage form
FR2950807B1 (fr) * 2009-10-06 2012-02-03 Lvmh Rech Composition cosmetique contenant des liposomes encapsules dans un compose oxazolidin-2-one
AU2011213557B2 (en) 2010-02-05 2015-05-07 Phosphagenics Limited Carrier comprising non-neutralised tocopheryl phosphate
RU2553350C2 (ru) 2010-03-30 2015-06-10 Фосфейдженикс Лимитед Трансдермальные пластыри
WO2011152832A1 (fr) 2010-06-04 2011-12-08 N.V. Perricone Llc Procédés d'utilisation de compositions à base de nitroalcène dans des applications dermatologiques pour prévenir ou traiter le vieillissement de la peau
US20120207838A1 (en) * 2011-02-10 2012-08-16 Perricone Nicholas V Treatment of Psoriasis Using Oral Dosage Forms of Nitrone Spin Traps
US8986739B2 (en) 2011-02-28 2015-03-24 Nicholas V. Perricone Treatment of urinary incontinence using nitrone spin traps
WO2012122586A1 (fr) 2011-03-15 2012-09-20 Phosphagenics Limited Nouvelle composition
CN103547258B (zh) * 2011-03-17 2017-10-20 特兰斯德梅尔生物工艺股份有限公司 局部一氧化氮系统及其使用方法
KR101943508B1 (ko) 2011-07-21 2019-01-30 (주)아모레퍼시픽 근육 피로 진정 효과를 갖는 화장료 조성물
US8871259B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Techniques and systems for treatment of neuropathic pain and other indications
US8871258B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Treatment and prevention of learning and memory disorders
US8871260B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Methods and compositions for muscular and neuromuscular diseases
US20160136169A1 (en) * 2012-09-19 2016-05-19 Transdermal Biotechnology, Inc. Systems and methods for delivery of tetrahydrobiopterin and related compounds
US8871256B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Methods and systems for treatment of inflammatory diseases with nitric oxide
US8871255B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Treatment of skin and soft tissue infection with nitric oxide
US8871257B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Prevention and treatment of cardiovascular diseases using systems and methods for transdermal nitric oxide delivery
US8871262B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Compositions and methods for treatment of osteoporosis and other indications
US8871254B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Systems and methods for treatment of acne vulgaris and other conditions with a topical nitric oxide delivery system
US8871261B2 (en) * 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Cancer treatments and compositions for use thereof
US9339457B2 (en) 2013-03-13 2016-05-17 Transdermal Biotechnology, Inc. Cardiovascular disease treatment and prevention
US9393264B2 (en) * 2013-03-13 2016-07-19 Transdermal Biotechnology, Inc. Immune modulation using peptides and other compositions
US20140271731A1 (en) * 2013-03-13 2014-09-18 Transdermal Biotechnology, Inc. Cardiovascular disease treatment and prevention
US9295636B2 (en) 2013-03-13 2016-03-29 Transdermal Biotechnology, Inc. Wound healing using topical systems and methods
US9314422B2 (en) * 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Peptide systems and methods for metabolic conditions
US9320758B2 (en) 2013-03-13 2016-04-26 Transdermal Biotechnology, Inc. Brain and neural treatments comprising peptides and other compositions
US9724419B2 (en) 2013-03-13 2017-08-08 Transdermal Biotechnology, Inc. Peptide systems and methods for metabolic conditions
US9314417B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Treatment of skin, including aging skin, to improve appearance
US20140271937A1 (en) * 2013-03-13 2014-09-18 Transdermal Biotechnology, Inc. Brain and neural treatments comprising peptides and other compositions
US20140271742A1 (en) * 2013-03-13 2014-09-18 Transdermal Biotechnology, Inc. Skin tanning using peptides and other compositions
US9393265B2 (en) 2013-03-13 2016-07-19 Transdermal Biotechnology, Inc. Wound healing using topical systems and methods
US20140271938A1 (en) 2013-03-13 2014-09-18 Transdermal Biotechnology, Inc. Systems and methods for delivery of peptides
US9314433B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Methods and systems for treating or preventing cancer
US9241899B2 (en) * 2013-03-13 2016-01-26 Transdermal Biotechnology, Inc. Topical systems and methods for treating sexual dysfunction
US9687520B2 (en) 2013-03-13 2017-06-27 Transdermal Biotechnology, Inc. Memory or learning improvement using peptide and other compositions
US9295647B2 (en) 2013-03-13 2016-03-29 Transdermal Biotechnology, Inc. Systems and methods for delivery of peptides
US9320706B2 (en) 2013-03-13 2016-04-26 Transdermal Biotechnology, Inc. Immune modulation using peptides and other compositions
US9849160B2 (en) * 2013-03-13 2017-12-26 Transdermal Biotechnology, Inc. Methods and systems for treating or preventing cancer
US9387159B2 (en) * 2013-03-13 2016-07-12 Transdermal Biotechnology, Inc. Treatment of skin, including aging skin, to improve appearance
US9750787B2 (en) * 2013-03-13 2017-09-05 Transdermal Biotechnology, Inc. Memory or learning improvement using peptide and other compositions
US9314423B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Hair treatment systems and methods using peptides and other compositions
US9295637B2 (en) 2013-03-13 2016-03-29 Transdermal Biotechnology, Inc. Compositions and methods for affecting mood states
US11484534B2 (en) 2013-03-14 2022-11-01 Abbvie Inc. Methods for treating HCV
AU2015240754B2 (en) 2014-04-02 2020-06-25 Abbvie Inc. Methods for treating HCV
US9707266B2 (en) 2014-11-18 2017-07-18 Transdermal Biotechnology, Inc. Methods and systems for delivery of ZW1 heptapeptide
US20160375017A1 (en) 2015-06-26 2016-12-29 Abbvie Inc. Solid Pharmaceutical Compositions for Treating HCV
EP3383371B1 (fr) 2015-12-09 2024-05-01 Avecho Biotechnology Limited Formulation pharmaceutique
CA3025208A1 (fr) * 2016-05-24 2017-11-30 Bol Pharma Ltd. Compositions comprenant du cannabidiol et de l'acide hyaluronique pour le traitement de maladies inflammatoires des articulations
US9949939B2 (en) * 2016-07-01 2018-04-24 Transdermal Biotechnology, Inc. Systems and methods for treating vitiligo
JP7198754B2 (ja) 2016-12-21 2023-01-04 アベーチョ バイオテクノロジー リミテッド 方法
JP6940889B2 (ja) * 2018-01-31 2021-09-29 株式会社ユニッシュ ホスファチジルコリン経皮吸収製剤
WO2022192135A1 (fr) * 2021-03-08 2022-09-15 Transdermal Biotechnology, Inc. Conjugués de dendrimère et de n-actyl-l-cystéine pour le traitement ou la prévention du vieillissement de la peau ou d'autres indications
WO2022221376A1 (fr) 2021-04-14 2022-10-20 Transdermal Biotechnology, Inc. Systèmes et méthodes de traitement du vitiligo à l'aide de pyruvate d'éthyle et d'autres composés
US20240122888A1 (en) 2022-10-03 2024-04-18 Transdermal Biotechnology, Inc. Systems and methods for delivery of phenylalanine and lactate
CN116077708A (zh) * 2023-01-04 2023-05-09 九九三零生物技术有限公司 一种负载药物的长效防感染抗菌消毒液晶膜及其制备方法
US11980651B1 (en) 2023-06-21 2024-05-14 Transdermal Biotechnology, Inc. Systems and methods for treatment of hearing using dihexa

Family Cites Families (161)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US561330A (en) * 1896-06-02 ljungstrom
US482554A (en) * 1892-09-13 Joseph galland
US722323A (en) * 1900-03-26 1903-03-10 Benjamin W Parker Letter-box.
US727323A (en) * 1901-10-04 1903-05-05 Harry Feder Dress-stay blank.
US2181390A (en) * 1933-08-09 1939-11-28 Arthur M Barrett Easel
US2182390A (en) * 1937-01-13 1939-12-05 William F Reardon Surgical device
US4251861A (en) * 1978-10-27 1981-02-17 Mago Gyula A Cellular network of processors
US4174296A (en) 1978-12-04 1979-11-13 American Lecithin Company Water soluble lecithin composition
JPS56135416A (en) * 1980-03-27 1981-10-22 Mitsubishi Chem Ind Ltd Pharmaceutical preparation for skin
NL193099C (nl) * 1981-10-30 1998-11-03 Novo Industri As Gestabiliseerde insuline-oplossing.
SE8206744D0 (sv) * 1982-11-26 1982-11-26 Fluidcarbon International Ab Preparat for kontrollerad avgivning av substanser
GB2134869A (en) * 1983-02-15 1984-08-22 Squibb & Sons Inc Method of preparing liposomes and products produced thereby
JPS607932A (ja) * 1983-06-29 1985-01-16 Dai Ichi Seiyaku Co Ltd リポソーム懸濁液およびその製法
JPS6058915A (ja) * 1983-09-12 1985-04-05 Fujisawa Pharmaceut Co Ltd 薬物含有脂質小胞体製剤
JPS60155109A (ja) * 1984-01-23 1985-08-15 Terumo Corp リポソ−ム製剤
US4708861A (en) * 1984-02-15 1987-11-24 The Liposome Company, Inc. Liposome-gel compositions
JPS6176414A (ja) * 1984-09-21 1986-04-18 Shionogi & Co Ltd リポソーム製剤の製法
US4624665A (en) 1984-10-01 1986-11-25 Biotek, Inc. Method of transdermal drug delivery
US4657661A (en) * 1985-12-11 1987-04-14 Chevron Research Company Process for improving the storage stability and bulk oxidation stability of lube base stocks derived from bright stock
WO1987004592A1 (fr) 1986-02-10 1987-08-13 Liposome Technology, Inc. Systeme d'administration liposomique a liberation entretenue
US5196410A (en) * 1986-10-31 1993-03-23 Pfizer Inc. Transdermal flux enhancing compositions
US4833468A (en) * 1987-10-14 1989-05-23 Unisys Corporation Layered network
US5656286A (en) * 1988-03-04 1997-08-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
US5153000A (en) * 1988-11-22 1992-10-06 Kao Corporation Phosphate, liposome comprising the phosphate as membrane constituent, and cosmetic and liposome preparation comprising the liposome
US5223476A (en) 1989-05-02 1993-06-29 Dai Nippon Insatsu Kabushiki Kaisha Heat transfer sheet
DE4002281A1 (de) * 1990-01-26 1991-08-01 Lohmann Therapie Syst Lts Transdermales therapeutisches system mit dem wirkstoff tulobuterol
IN172208B (fr) * 1990-04-02 1993-05-01 Sint Sa
JP3765579B2 (ja) * 1990-08-24 2006-04-12 イーデーエーアー アーゲー 作用物質投与用超微小滴状調剤
US6165500A (en) * 1990-08-24 2000-12-26 Idea Ag Preparation for the application of agents in mini-droplets
CA2053462A1 (fr) 1990-10-22 1992-04-23 Yoshiaki Yano Composition adhesive utilisee a des fins medicales
US5674912A (en) 1991-03-01 1997-10-07 Warner-Lambert Company Sunscreen-wound healing compositions and methods for preparing and using same
US5874479A (en) * 1991-03-01 1999-02-23 Warner-Lambert Company Therapeutic permeation enhanced-wound healing compositions and methods for preparing and using same
HU209605B (en) * 1991-04-15 1994-09-28 Chinoin Gyogyszer Es Vegyeszet Process for production of wather-free transdermal preparation
US5120561A (en) 1991-04-25 1992-06-09 American Lecithin Company Food composition and method
FR2676649B1 (fr) * 1991-05-22 1994-02-25 Lvmh Recherche Composition cosmetique ou pharmaceutique, notamment dermatologique, destinee a favoriser la pigmentation de la peau ou des cheveux, contenant un extrait de cyperus et son procede de fabrication.
SE9101709L (sv) * 1991-06-03 1992-12-04 Karlshamns Lipidteknik Ab Lipidderivat som diagnostikum eller kontrastmedel
US5439967A (en) * 1991-09-17 1995-08-08 Micro Vesicular Systems, Inc. Propylene glycol stearate vesicles
EP0643620B1 (fr) * 1991-10-04 1999-07-21 Gs Development Ab Particules, procede de preparation desdites particules et utilisations
US5206219A (en) * 1991-11-25 1993-04-27 Applied Analytical Industries, Inc. Oral compositions of proteinaceous medicaments
DE4208552A1 (de) 1992-03-17 1993-09-23 Liedtke Pharmed Gmbh Topische arzneiformen mit insulin
US5814666A (en) * 1992-04-13 1998-09-29 The United States As Represented By The Department Of Health And Human Services Encapsulated and non-encapsulated nitric oxide generators used as antimicrobial agents
ES2221921T3 (es) * 1992-07-13 2005-01-16 Shiseido Company, Ltd. Composicion para preparacion dermatologica.
US5308625A (en) * 1992-09-02 1994-05-03 Cygnus Therapeutic Systems Enhancement of transdermal drug delivery using monoalkyl phosphates and other absorption promoters
DE4336557C2 (de) 1993-05-06 1997-07-17 Lohmann Therapie Syst Lts Estradiolhaltiges transdermales therapeutisches System, Verfahren zu seiner Herstellung und seine Verwendung
US5576016A (en) * 1993-05-18 1996-11-19 Pharmos Corporation Solid fat nanoemulsions as drug delivery vehicles
US5555405A (en) * 1993-07-06 1996-09-10 Digital Equipment Corporation Method and apparatus for free space management in a forwarding database having forwarding entry sets and multiple free space segment queues
AU679553B2 (en) * 1993-07-07 1997-07-03 European Computer-Industry Research Centre Gmbh Database structures
US5853755A (en) * 1993-07-28 1998-12-29 Pharmaderm Laboratories Ltd. Biphasic multilamellar lipid vesicles
ATE155649T1 (de) * 1994-02-01 1997-08-15 Theodor Krall Verfahren zur herstellung von bakteriziden/fungiziden kunststoffkörpern
NZ279953A (en) * 1994-02-04 1998-02-26 Scotia Lipidteknik Ab Lipid-polar solvent bilayer carrier preparation (eg liposomes) comprising digalactosyldiacylglycerols as the bilayer material
EP0752855B1 (fr) * 1994-03-30 1999-06-09 Gs Development Ab Utilisation d'esters d'acides gras comme substances bioadherentes
FI100692B (fi) * 1994-05-24 1998-02-13 Leiras Oy Menetelmä farmaseuttisten koostumusten valmistamiseksi, jolloin koostu mukset pohjautuvat mikroemulsiogeeleihin sekä uusia mikroemulsioihin p ohjautuvia geelejä
US5504117A (en) * 1994-05-27 1996-04-02 Neptune Pharmaceutical Corporation Pharmacologic preparation for the treatment of anal disorders
ES2292402T3 (es) * 1994-05-27 2008-03-16 Strakan International Limited Composicion de donador de oxido nitrico y metodo para el tratamiento de afecciones anales.
SE518578C2 (sv) * 1994-06-15 2002-10-29 Gs Dev Ab Lipidbaserad komposition
US5787430A (en) * 1994-06-30 1998-07-28 International Business Machines Corporation Variable length data sequence backtracking a trie structure
JP3901213B2 (ja) 1994-08-05 2007-04-04 インファルマ・ソシエテ・アノニム ホスファチジルコリンとプロスタグランジンｅ１及び／又はトロキサールチンとの複合体を含有する、勃起不能の局所治療のための製剤
US5761440A (en) * 1994-09-15 1998-06-02 International Business Machines Corporation System and method utilizing multiple search trees to route data within a data processing network
US5707641A (en) * 1994-10-13 1998-01-13 Pharmaderm Research & Development Ltd. Formulations comprising therapeutically-active proteins or polypeptides
IL115693A (en) * 1994-10-25 2000-08-13 Revlon Consumer Prod Corp Cosmetic compositions with improved transfer resistance
US5858398A (en) * 1994-11-03 1999-01-12 Isomed Inc. Microparticular pharmaceutical compositions
EP0733358A3 (fr) * 1995-03-21 1998-05-20 Novartis AG Nanosuspensions pour application intraveineuse
CA2181390C (fr) 1995-07-18 2001-04-24 Pankaj Modi Formulations a base de phospholipides
US5879690A (en) * 1995-09-07 1999-03-09 Perricone; Nicholas V. Topical administration of catecholamines and related compounds to subcutaneous muscle tissue using percutaneous penetration enhancers
US5898038A (en) * 1996-03-19 1999-04-27 Board Of Regents, The University Of Texas System Treatment of osteoporosis and metabolic bone disorders with nitric oxide substrate and/or donors
US5869539A (en) * 1996-04-17 1999-02-09 Board Of Regents, The University Of Texas System Emulsions of perfluoro compounds as solvents for nitric oxide (NO)
US6214375B1 (en) * 1996-07-16 2001-04-10 Generex Pharmaceuticals, Inc. Phospholipid formulations
DE19640092A1 (de) 1996-09-28 1998-04-16 Beiersdorf Ag Strukturen mit Lipid-Doppelmembranen, in deren lipophilen Bereich längerkettige Moleküle eintauchen oder durch hydrophobe Wechselwirkungen an solche Moleküle angedockt sind
US5891472A (en) * 1996-11-19 1999-04-06 Meri Charmyne Russell Treatment of equine laminitis
FR2755856B1 (fr) 1996-11-21 1999-01-29 Merck Clevenot Laboratoires Microcapsules de chitine ou de derives de chitine contenant une substance hydrophobe, notamment un filtre solaire et procede de preparation de telles microcapsules
AUPO379596A0 (en) 1996-11-22 1996-12-19 Soltec Research Pty Ltd Percutaneous delivery system
US5909440A (en) * 1996-12-16 1999-06-01 Juniper Networks High speed variable length best match look-up in a switching device
US5776494A (en) 1996-12-20 1998-07-07 The Procter & Gamble Company Pharmaceuticals compositions containing gellants in the form of alkyl amides of di-and tri-carboxylic acids
JPH10194994A (ja) 1997-01-16 1998-07-28 Pola Chem Ind Inc 吸収促進組成物
US6021131A (en) * 1997-07-08 2000-02-01 Lucent Technologies, Inc. Sorting networks having enhanced layout
JPH1179975A (ja) 1997-09-05 1999-03-23 Mitsui Chem Inc マイクロカプセルの調製法
US6018524A (en) * 1997-09-09 2000-01-25 Washington University Scalable high speed IP routing lookups
US6266706B1 (en) * 1997-09-15 2001-07-24 Effnet Group Ab Fast routing lookup system using complete prefix tree, bit vector, and pointers in a routing table for determining where to route IP datagrams
US6207713B1 (en) * 1997-09-17 2001-03-27 Eric T. Fossel Topical and oral delivery of arginine to cause beneficial effects
US6041053A (en) * 1997-09-18 2000-03-21 Microsfot Corporation Technique for efficiently classifying packets using a trie-indexed hierarchy forest that accommodates wildcards
US6563823B1 (en) * 1997-10-30 2003-05-13 Marconi Communications, Inc. Multi-resolution tree for longest match address lookups
US6061712A (en) * 1998-01-07 2000-05-09 Lucent Technologies, Inc. Method for IP routing table look-up
US6289013B1 (en) * 1998-02-09 2001-09-11 Lucent Technologies, Inc. Packet filter method and apparatus employing reduced memory
US6341130B1 (en) * 1998-02-09 2002-01-22 Lucent Technologies, Inc. Packet classification method and apparatus employing two fields
US6092072A (en) * 1998-04-07 2000-07-18 Lucent Technologies, Inc. Programmed medium for clustering large databases
BE1011899A6 (fr) * 1998-04-30 2000-02-01 Ucb Sa Compositions pharmaceutiques gelifiables utilisables.
US6522632B1 (en) * 1998-05-06 2003-02-18 Avici Systems Apparatus and method for efficient prefix search
US6103275A (en) * 1998-06-10 2000-08-15 Nitric Oxide Solutions Systems and methods for topical treatment with nitric oxide
US6157955A (en) * 1998-06-15 2000-12-05 Intel Corporation Packet processing system including a policy engine having a classification unit
WO2000003522A1 (fr) * 1998-07-08 2000-01-20 Broadcom Corporation Procede d'envoi de paquets entre des ports de liaisons longue distance de commutateurs de reseau
US6212184B1 (en) * 1998-07-15 2001-04-03 Washington University Fast scaleable methods and devices for layer four switching
JP2000086501A (ja) 1998-09-11 2000-03-28 Sankyo Co Ltd ヒトカルシトニンのリポソーム製剤
US6193997B1 (en) * 1998-09-27 2001-02-27 Generex Pharmaceuticals Inc. Proteinic drug delivery system using membrane mimetics
US6936044B2 (en) * 1998-11-30 2005-08-30 Light Bioscience, Llc Method and apparatus for the stimulation of hair growth
US6391869B1 (en) * 1998-12-14 2002-05-21 Cellergy Pharmaceuticals, Inc. Compositions and methods for the treatment of anorectal disorders
US6294192B1 (en) * 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
AU5409699A (en) 1999-07-05 2001-01-22 Idea Ag A method for the improvement of transport across adaptable semi-permeable barriers
EP1246608A4 (fr) 2000-01-05 2005-05-18 Imarx Therapeutics Inc Formulations pharmaceutiques pour l'administration de medicaments ayant une faible solubilite aqueuse
US6581106B1 (en) * 2000-01-13 2003-06-17 Pierluigi Crescenzi Fast address lookup in routing tables
ATE319249T1 (de) * 2000-01-27 2006-03-15 Ibm Verfahren und vorrichtung für klassifizierung von datenpaketen
BR0005797A (pt) * 2000-03-20 2001-10-16 Abbott Lab Métodos para o tratamento de disfunção sexual com apomorfina em nìveis de concentração plasmática especificados
US6191121B1 (en) * 2000-04-06 2001-02-20 Nicholas V. Perricone Treatment of skin damage using polyenylphosphatidylcholine
US6932963B2 (en) 2000-06-23 2005-08-23 Nicholas V. Perricone Treatment of skin wounds using polyenylphosphatidylcholine and alkanolamines
BRPI0113085B1 (pt) * 2000-08-11 2017-09-19 R. Whitlock David Preparation to be applied to a surface of an individual understanding ammonia oxidizing bacteria that metabolize transparation, and clothing article
US6780849B2 (en) * 2000-12-21 2004-08-24 Scimed Life Systems, Inc. Lipid-based nitric oxide donors
US6555573B2 (en) 2000-12-21 2003-04-29 The Quigley Corporation Method and composition for the topical treatment of diabetic neuropathy
US20020131994A1 (en) * 2001-01-10 2002-09-19 Schur Henry B. Non-irritating formulation for the transdermal delivery of substances
KR100508695B1 (ko) 2001-02-13 2005-08-17 한국과학기술연구원 인슐린의 경구투여용 제형과 그의 제조방법
KR20020066778A (ko) 2001-02-13 2002-08-21 한국과학기술연구원 체내 난흡수 물질의 흡수촉진용 조성물과 제형 및 그의제조방법
US7008646B2 (en) * 2001-02-20 2006-03-07 Patrick Thomas Spicer Cubic liquid crystalline compositions and methods for their preparation
US6936187B2 (en) * 2001-02-21 2005-08-30 Matthew Lawrence Lynch Functionalized cubic liquid crystalline phase materials and methods for their preparation and use
SE0100901D0 (sv) * 2001-03-15 2001-03-15 Astrazeneca Ab New composition
US6538061B2 (en) * 2001-05-16 2003-03-25 General Electric Company Cosmetic compositions using polyether siloxane copolymer network compositions
US6858398B2 (en) * 2001-08-14 2005-02-22 Immunosciences Lab., Inc. Saliva test for detection of food allergy and intolerance
US6568061B2 (en) * 2001-09-21 2003-05-27 Atlantic Research Corporation Method for controlling composite preform elements during processing
US8435942B2 (en) * 2002-05-31 2013-05-07 Transdermal Biotechnology, Inc. Methods for formulating stabilized insulin compositions
US20040018237A1 (en) * 2002-05-31 2004-01-29 Perricone Nicholas V. Topical drug delivery using phosphatidylcholine
US20100311696A1 (en) * 2002-05-31 2010-12-09 Perricone Nicholas V Topical skin treatment composition
US20020182162A1 (en) * 2002-08-07 2002-12-05 Mohsen Shahinpoor Nitric oxide (NO) donor+cGMP-PDE5 inhibitor as a topical drug for enhanced hair growth
ES2362412T3 (es) 2002-12-31 2011-07-05 Transdermal Biotechnology, Inc. Composiciones estables para el suministro tópico de fármacos.
US7390507B2 (en) * 2004-04-13 2008-06-24 Ruwart Mary J Compositions and methods for the treatment of radiation burns and other traumatic skin conditions
WO2006042701A1 (fr) * 2004-10-18 2006-04-27 Polymun Scientific Immunbiologische Forschung Gmbh Composition liposomale contenant un principe actif destine a relaxer la musculature lisse, utilisation de cette composition et son utilisation therapeutique
CA2588744A1 (fr) * 2004-11-29 2006-06-01 The University Of Akron Dispositifs donneurs de monoxyde d'azote topiques et leurs methodes d'utilisation a des fins therapeutiques
US8247460B2 (en) * 2006-02-03 2012-08-21 Giulio Cossu Method of treatment for muscular dystrophy
PT1996710T (pt) * 2006-03-09 2019-10-25 Salix Pharmaceuticals Inc Preparação da disfunção anti-rectal de rifaximina.
US7976743B2 (en) * 2006-10-16 2011-07-12 Northwestern University Gas-containing liposomes
WO2009155689A1 (fr) * 2008-06-24 2009-12-30 Micropharma Limited Dispositif à base d’oxyde nitrique et procédé de cicatrisation de blessures, traitement de troubles dermatologiques et d’infections microbiennes
CA2796280A1 (fr) * 2010-04-15 2011-10-20 The Royal Institution For The Advancement Of Learning / Mcgill Universit Y Traitements topiques de la douleur
US8591876B2 (en) * 2010-12-15 2013-11-26 Novan, Inc. Methods of decreasing sebum production in the skin
CN103547258B (zh) * 2011-03-17 2017-10-20 特兰斯德梅尔生物工艺股份有限公司 局部一氧化氮系统及其使用方法
US8871258B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Treatment and prevention of learning and memory disorders
US8871259B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Techniques and systems for treatment of neuropathic pain and other indications
US8871255B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Treatment of skin and soft tissue infection with nitric oxide
US8871260B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Methods and compositions for muscular and neuromuscular diseases
US8871261B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Cancer treatments and compositions for use thereof
US8871262B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Compositions and methods for treatment of osteoporosis and other indications
US8871257B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Prevention and treatment of cardiovascular diseases using systems and methods for transdermal nitric oxide delivery
US8871254B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Systems and methods for treatment of acne vulgaris and other conditions with a topical nitric oxide delivery system
US8871256B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Methods and systems for treatment of inflammatory diseases with nitric oxide
US9387159B2 (en) 2013-03-13 2016-07-12 Transdermal Biotechnology, Inc. Treatment of skin, including aging skin, to improve appearance
US9849160B2 (en) 2013-03-13 2017-12-26 Transdermal Biotechnology, Inc. Methods and systems for treating or preventing cancer
US9314433B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Methods and systems for treating or preventing cancer
US9241899B2 (en) 2013-03-13 2016-01-26 Transdermal Biotechnology, Inc. Topical systems and methods for treating sexual dysfunction
US9687520B2 (en) 2013-03-13 2017-06-27 Transdermal Biotechnology, Inc. Memory or learning improvement using peptide and other compositions
US9724419B2 (en) 2013-03-13 2017-08-08 Transdermal Biotechnology, Inc. Peptide systems and methods for metabolic conditions
US9314417B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Treatment of skin, including aging skin, to improve appearance
US9314422B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Peptide systems and methods for metabolic conditions
US9295637B2 (en) 2013-03-13 2016-03-29 Transdermal Biotechnology, Inc. Compositions and methods for affecting mood states
US20140271937A1 (en) 2013-03-13 2014-09-18 Transdermal Biotechnology, Inc. Brain and neural treatments comprising peptides and other compositions
US9314423B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Hair treatment systems and methods using peptides and other compositions
US9295647B2 (en) 2013-03-13 2016-03-29 Transdermal Biotechnology, Inc. Systems and methods for delivery of peptides
US20140271938A1 (en) 2013-03-13 2014-09-18 Transdermal Biotechnology, Inc. Systems and methods for delivery of peptides
US9393265B2 (en) 2013-03-13 2016-07-19 Transdermal Biotechnology, Inc. Wound healing using topical systems and methods
US9339457B2 (en) 2013-03-13 2016-05-17 Transdermal Biotechnology, Inc. Cardiovascular disease treatment and prevention
US9295636B2 (en) 2013-03-13 2016-03-29 Transdermal Biotechnology, Inc. Wound healing using topical systems and methods
US9393264B2 (en) 2013-03-13 2016-07-19 Transdermal Biotechnology, Inc. Immune modulation using peptides and other compositions
US9320758B2 (en) 2013-03-13 2016-04-26 Transdermal Biotechnology, Inc. Brain and neural treatments comprising peptides and other compositions
US9750787B2 (en) 2013-03-13 2017-09-05 Transdermal Biotechnology, Inc. Memory or learning improvement using peptide and other compositions
US9320706B2 (en) 2013-03-13 2016-04-26 Transdermal Biotechnology, Inc. Immune modulation using peptides and other compositions
US20140271731A1 (en) 2013-03-13 2014-09-18 Transdermal Biotechnology, Inc. Cardiovascular disease treatment and prevention
US20140271742A1 (en) 2013-03-13 2014-09-18 Transdermal Biotechnology, Inc. Skin tanning using peptides and other compositions

Also Published As

Publication number Publication date
CA2487305A1 (fr) 2003-12-11
US20150238608A1 (en) 2015-08-27
US20060275353A1 (en) 2006-12-07
US20150004196A1 (en) 2015-01-01
ES2632912T3 (es) 2017-09-18
US7182956B2 (en) 2007-02-27
US9050248B2 (en) 2015-06-09
US20130331319A1 (en) 2013-12-12
CN1671409A (zh) 2005-09-21
US20040018237A1 (en) 2004-01-29
AU2003231943A1 (en) 2003-12-19
EP1509243B1 (fr) 2017-03-22
US20110123577A1 (en) 2011-05-26
US20060105955A1 (en) 2006-05-18
US9060925B2 (en) 2015-06-23
EP1509243A1 (fr) 2005-03-02
US20130330380A1 (en) 2013-12-12
US20110130330A1 (en) 2011-06-02
US20060127469A1 (en) 2006-06-15
CN100509054C (zh) 2009-07-08
US20040197391A1 (en) 2004-10-07
IL165480A0 (en) 2006-01-15
WO2003101480A1 (fr) 2003-12-11
US20100292139A1 (en) 2010-11-18
JP2005531595A (ja) 2005-10-20
US8273711B2 (en) 2012-09-25
AU2003231943B2 (en) 2006-03-16
US20130330381A1 (en) 2013-12-12
US20130331318A1 (en) 2013-12-12
EP1509243A4 (fr) 2009-06-24
IL165480A (en) 2012-10-31

Similar Documents

Publication Publication Date Title
HK1083009A1 (en) Topical drug delivery using phosphatidylcholine
GEP20084561B (en) System and method for controlled drug release and transdermal drug delivery device
HK1081878A1 (en) Stable topical drug delivery compositions
AU2001254711A1 (en) Sustained release vitamin composition
AU1534699A (en) Osmotic dosage form comprising first and second coats
TW200502017A (en) Active agent delivery device having composite members
MXPA03010295A (es) Sistema para administrar productos cosmeticos y farmaceuticos.
WO2006036970A3 (fr) Procede permettant d'epaissir un revetement a l'aide d'un medicament
TR200002786T2 (tr) Meloksikam için yeni galenik bir formülasyon.
UA88464C2 (ru) Способ дермального введения метадоновой композиции с обеспечением системного действия
AU4923500A (en) Device and method for increasing the transdermal permeation of medicaments
WO2004030743A3 (fr) Methode et dispositif d'administration de medicaments presentant des microprojections revetues comprenant des vasoconstricteurs
MXPA06012960A (es) Administracion transdermal de ficotoxinas.
AU4231400A (en) Pre-formed sheet devices suitable for topical application
MXPA04005980A (es) Un metodo y dispositivo para reducir dosificacion terapeutica.
AU2084801A (en) Antiviral medication
AR021459A1 (es) PARCHE QUE CONTIENE ESTRADIOL PARA LA APLICACIoN PERCUTÁNEA DE HORMONAS.
AU2002214389A1 (en) Pharmaceutical composition containing honey for the treatment of wounds
AU2003279570A1 (en) Delivery agent, method of delivering a target substance to cells, method for producing delivery agent, composition for producing delivery agent, and kit for producing delivery agent
JO2492B1 (en) A pharmaceutical formula in the form of aqueous gel for the skin use of its active ingredients
AU2002328873A1 (en) Dosage forms comprising particles containing active ingredient for application on the skin or mucous membrane
MXPA04012732A (es) Plataforma para formulaciones transdermicas (pft).
AU3603597A (en) Drug delivery devices and process of manufacture
WO2006113796A3 (fr) Matieres cellulosiques microbiennes pouvant etre utilisees dans des systemes d'administration de medicaments transdermiques, et procedes de fabrication et utilisation de ces matieres
UA87291C2 (ru) Пероральное пленкообразное лекарственное средство дезоксипеганина и способ его применения

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20180602